<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553589</url>
  </required_header>
  <id_info>
    <org_study_id>NL63773</org_study_id>
    <nct_id>NCT03553589</nct_id>
  </id_info>
  <brief_title>Biomarkers for Diagnosis and Prognosis of Endometrial Carcinoma</brief_title>
  <acronym>BioEndoCar</acronym>
  <official_title>Minimally and Non-invasive Methods for Early Detection and Progression of Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrea Romano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ljubljana, Faculty of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Lublin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Ziekenhuis Maastricht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometrial cancer (EC) is the most frequent gynecological malignancy but there is currently
      lack of both non-invasive diagnostic tools and novel markers to stratify patients based on
      their risk of future recurrence. Patient care could be improved by advances in these two
      aspects.

      In the present study, the investigators aim to identify diagnostic serum metabolite and
      protein biomarker signatures for early detection of cancer in asymptomatic high-risk
      population and prognostic biomarkers for selection of patients with poor prognosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Endometrial cancer (EC) is the most frequent gynaecological malignancy in the
      developed world. Optimal treatment of EC depends on early diagnostics and pre-operative
      stratification to appropriately select the extent of surgery and to plan further therapeutic
      approach. Currently, invasive endometrial histology is the gold standard for diagnosis, as
      there are no valid non-invasive methods available, and patient stratification is based on
      histopathology and surgical findings. There is a great need for efficient and reliable
      screening test for asymptomatic women with high risk of EC including Lynch syndrome patients
      and tamoxifen treated patients. In addition, a prognostic test is needed to stratify
      pre-operatively EC patients with high risk of progression in need of radical surgery together
      with adjuvant chemo/ratio therapy from EC patients with good prognosis. In this project the
      investigators are addressing this lack of non-invasive diagnostic and prognostic biomarkers
      of EC.

      Objective: the investigators aim to identify diagnostic serum metabolite and protein
      biomarker signatures for early detection of cancer in asymptomatic high-risk population and
      (secondary objective) prognostic biomarkers for selection of patients with poor prognosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Creation of a diagnostic algorithm</measure>
    <time_frame>2020-2021</time_frame>
    <description>Blood metabolome and proteome will be analysed and bioinformatics/biostatistical analysis will be used to derive diagnostic algorithms based on blood metabolites, proteins and clinical data. Algorithms in the biomarker discovery study will be developed by comparing EC and patients with benign uterine pathologies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Creation of a prognostic algorithm</measure>
    <time_frame>2021</time_frame>
    <description>Blood metabolome and proteome will be analysed and bioinformatics/biostatistical analysis will be used to derive prognostic algorithms based on blood metabolites, proteins, clinical data at baseline and follow up information. Algorithms in the biomarker discovery study will be developed by comparing EC patients with low risk and high risk for cancer progression and recurrence.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Women older than 18 years and diagnosed with endometrial cancer will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <description>Women older than 18 years and with a benign endometrial disturbance will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling (10 mL) prior to standard care (e.g. surgery, medical treatment)</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women older than 18 years and able to sign the informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria Cases:

          -  endometrioid, serous, clear cell or mucinous endometrial cancer

          -  dedifferentiated endometrial cancer

          -  high grade or low grade endometrial cancer

        Inclusion Criteria Controls:

          -  benign uterine diseases, e.g. myoma uteri, prolapsed uterus

          -  prophylactic hysterectomy for Lynch syndrome

        Exclusion Criteria Cases:

          -  atypical hyperplasia

          -  other types of cancer

          -  sarcoma uteri

          -  previous diagnosis of endometrial cancer

        Exclusion Criteria Controls:

          -  any cancer

          -  benign ovarian diseases

          -  previous EC

          -  pregnancy at the time of enrollment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Romano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tea Lanišnik Rižner, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, University of Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Romano, Dr.</last_name>
    <phone>+31 433881286</phone>
    <email>a.romano@maastrichtuniversity.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roy Kruitwagen, Prof. Dr.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Romano, dr.</last_name>
      <phone>+31 43 3881286</phone>
      <email>a.romano@maastrichtuniversity.nl</email>
    </contact>
    <investigator>
      <last_name>Roy Kruitwagen, Prof. dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medical Centre</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marlies Bongers, Prof. dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lublin Medical University</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Semczuk, Prof</last_name>
      <phone>+48 81 7244262</phone>
      <email>andrzej.semczuk@umlub.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine, University of Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tea Lanišnik Rižner, Prof. dr.</last_name>
      <phone>+386 1543 7657</phone>
      <email>tea.lanisnik-rizner@mf.uni-lj.si</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Centre, Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Špela Smrkolj, Prof. Dr.</last_name>
      <email>spela.smrkolj@kclj.si</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovenia</country>
  </location_countries>
  <link>
    <url>https://bioendocar.eu/</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>December 3, 2018</last_update_submitted>
  <last_update_submitted_qc>December 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Ziekenhuis Maastricht</investigator_affiliation>
    <investigator_full_name>Andrea Romano</investigator_full_name>
    <investigator_title>PhD. Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>metabolomics</keyword>
  <keyword>proteomics</keyword>
  <keyword>early diagnosis</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be discussed within the team, put planned</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

